Roche Begins Phase III Clinical Trial of Actemra/RoActemra in Hospitalized Patients with Severe COVID-19 Pneumonia
Basel, Switzerland based biotech giant Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR), to evaluate the safety and efficacy of Actemra®/RoActemra® (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.
This is the first global study of Actemra/RoActemra in this setting and is expected to begin enrolling as soon as possible in early April with a target of approximately 330 patients globally, including the US. The primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables.
To date, there are several independent clinical trials exploring the efficacy and safety of Actemra/RoActemra for the treatment of patients with COVID-19 pneumonia. Actemra/RoActemra has been included in the 7th updated diagnosis and treatment plan for COVID-19 issued by China's National Health Commission (NHC) on March 3, 2020.
This new trial is considered as vital because there are no well-controlled studies and limited published evidence on the safety or efficacy of Actemra/RoActemra in the treatment of patients suffering from COVID-19. In addition, Actemra/RoActemra is not currently approved for this use by any health authorities, including the US Food and Drug Administration (FDA).
In addition to initiating this trial, Roche received FDA Emergency Use Authorisation for the cobas® SARS-CoV-2 Test on March 13, 2020, to detect the novel virus that causes COVID-19 disease.
Tagged with: Roche
Previous storyBluWave-ai Closes $3.9M Seed Funding
Next storyBillon Group Raises $6M in Series A Financing
Flatiron Health Raises $175M in Series C Funding
By FinSMEs	Published on January 6, 2016 April 27, 2016
SwitzerlandUSA
Roche Acquires Bina Technologies
Noema Pharma Raises CHF54M in Series A Financing